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Rapport de synthèse 
Le ganglion sentinelle (GS) se défini comme le premier ganglion de la chaîne 
ganglionnaire qui draine le territoire anatomique où siège une tumeur et, par 
conséquent, celui ayant le plus de possibilités de recevoir des métastases. La 
combinaison des deux techniques de détection du GS existantes, 
lymphoscintigraphie et coloration, permettent de déceler le GS dans 95-100% des 
cas. Le taux d'attente métastatique du GS varie entre 16 et 21 % des patients. Dans 
50 à 87% des cas, le GS est le seul site de métastase et la probabilité de trouver des 
micro-métastases dans des ganglions appartenant aux relais supérieurs sans 
atteinte du GS est estimée à moins de 2%. Ces chiffres relèvent l'importance de la 
détection du GS. L'emploi de cette technique offre de nombreux avantages par 
rapport à la lymphadénéctomie élective que nous décrirons. Selon Rousseau et al., il 
existe une probable association entre le statut du GS et la survie de la maladie. Cette 
interprétation et celles d'autres auteurs soulignent la pertinence clinique du statut du 
GS dans le mélanome. En ce qui concerne la survie sans maladie (DFS) et la survie 
globale (OS), aucune différence significative n'a été observée entre les patients 
ayant subi une résection complète immédiate des ganglions lymphatiques et ceux 
qui d'abord ont subi une résection chirurgicale et analyse du GS secondaire, suivies 
par une dissection élective en cas de positivité. L'objectif de cette étude prospective 
était d'évaluer la pertinence de la positivité tumorale du GS dans l'évaluation des 
risques de rechute du mélanome. 
Cette étude a confirmé l'intérêt de la scintigraphie des ganglions lymphatiques 
(associée à la technique de coloration par bleu et celle de détection par sonde 
portable) dans l'identification du GS comme approche thérapeutique au stade 
précoce du mélanome. Elle a montré, en autre, que le statut du GS et l'indice de 
Breslow sont des facteurs de risque indépendants importants de rechute chez des 
patients atteints d'un mélanome au stade précoce. La combinaison de ces deux 
paramètres a permis de créer des groupes de patients à risque de rechute différents 
qui pourraient conduire à l'adaptation des protocoles de thérapie en fonction de ces 
risques. 
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Summary 
The clinical relevance of sentine! lymph node {SLN) 
analysis was evaluated prospectively and compared with 
other known risk factors of relapse in early stage mel-
anoma. Surgery was guided by lymphoscinti-
graphy, blue dye and gamma probe detection. SLN were 
analysed by haematoxylin eosin (HE) histochemistry and 
multimarker immunohistochemistry {IHC). Disease free 
survival {DFS) was evaluated with Kaplan-Meier plots ac-
cording ta different parameters and Cox analyses of vari-
ance. Resulls: From 210 patients a total of 381 SLN were 
excised. Lymphoscintigraphy identified ail excised SLN with 
only 2 false positive lymphatic lakes. Fifty patients (24%) 
had tumour positive SLN. With a mean follow-up of 31.3 
months, 29 tumour recurrences were observed, 19 {38%) 
in 50 SLN positive and l 0 {6%) in 160 SLN negative pa-
tients. Strong predictive factors for early relapse 
(p < 0.0005) were SLN positivity and a high Breslow 
index. SLN tumour positivity is an indepen-
dent factor of high risk for early relapse with a higher power 
of discrimination thon the Breslow index. 
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T he application of the sentine! lymph node (SLN) technique to melanoma has been introduced in 
1992 by Morton et al. (7) and extended 
with scintigraphy by Alex et al. in 1993 
(1). The combination of lymphoscinti-
graphy with the blue dye technique allows 
identifying the SLN in 95 to 100% of the 
Schlüsselwfüter 
Wêichterlymphknoten, Melanom, Breslow-lndex, Risiko-
faktor, Rezidiv 
Zusammenfassung 
Die klinische Bedeutung des Wêichterlymphkno-
ten{SLN)-Befalls wurde prospektiv in Bezug ouf dos Früh-
auftreten eines Rezidivs analysiert und mit anderen be-
kannten Risikofaktoren beim Melanom im Frühstadium 
verglichen. Nach der Resektion, gestützt ouf 
Szintigraphie, Patentblau V und intraoperative Gamma-
Sondenmessung, wurden die SLN mit Hêimatoxylin-
Eosin(HE)-Fêirbung und Multimarker-lmmunohistochemie 
{ICH) untersucht. Tumorfreie Überlebenszeit wurde für ver-
schiedene Parameter nach der Kaplan-Meier-Methode und 
der Cox-Varianzanalyse analysiert. Ergeb11isse: Bei 210 
Patienten wurden 381 SLN untersucht. Die Szintigraphie 
identifizierte aile Lymphknoten, mit zwei falsch positiven 
Ergebnissen. Fünfzig Patienten (2 4%) wiesen einen Tu-
morbefall des SLN ouf. Bei einer mittleren Beobachtungs-
zeitvon 31,3 Monaten wurden 29 Rezidive festgestellt, da-
von 19 (38%) bei 50 SLN-positiven und l 0 {6%) bei 160 
SLN-negativen Patienten. Den hochsten prêidiktiven Wert 
(p < 0,0005) für ein frühzeitiges Rezidiv wiesen SLN-Be-
fall und Breslow-lndex ouf. Schluss!olgenmg: SLN-Befall 
ist ein unabhêingiger Risikofaktor für ein früh rezidivieren-
des Melanom mit besserer Diskriminanz ais der Breslow-
lndex. 
patients. Metastatic SLN have been found 
in 16 to 21% of patients (5, 7, 9, 10, 
12-14). In case of SLN positivity in mel-
anoma, SLN was the unique site of meta-
stasis in 50 to 87% of patients submitted 
to elective lymphadenectomy. Fur-
thermore, metastases that bypassed the 
SLN were found in less than 2% of pa-
tients (5, 9, 10, 13). These data show the 
importance of SLN analysis in patients 
with melanoma. The selective excision of 
sentinel lymph node(s) offers several ad-
vantages compared to elective lymph 
node dissection: First, the large majority 
of patients without lymph node disease 
will not undergo unnecessary lymph node 
dissection, a procedure connected with a 
high incidence of complications such as 
wound infection, seroma formation and 
lymphoedema. Secondly, the sentine! 
node can be analysed most carefully 
using multiple slicing combined with de-
tailed histologie and immunhistologic 
analysis and reverse transcription-
polymerase chain reaction (RT-PCR). 
Such an extended analysis cannot be ap-
plied routinely to the multiple nodes from 
elective lymph node dissections. 
Rousseau et al. (12) showed that strat-
ification of melanoma patients according 
to the American Joint Committee on 
Cancer (AJCC) staging criteria revealed an 
increasing risk of SLN metastases with 
successive stage groups. According to 
these authors, the ability oftheAJCC stag-
ing system to predict survival was likely 
due to its ability to predict the risk of occult 
nodal, notably SLN disease, given the sig-
nificant association of SLN status and sur-
vival. This interpretation again highlights 
the clinical relevance of the SLN status in 
melanoma. 
With regard to disease free survival 
(DFS) and overall survival (OS), no signifi-
cant difference was observed between pa-
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tients having undergone immediate com-
plete resection of lymph nodes of the pri-
mary basin and patients who first had sur-
gical resection and analysis of the SLN fol-
lowed by secondary elective lymph node 
dissection in case of positivity ( 4). 
Only afew studies focus on long-termre-
sults of selective sentine! node surgery due 
to the recent development of the method and 
the fact that randomised studies are on-
going. The goal of this prospective study 
was to evaluate the relevance of SLN tu-
mour positivity in relapse risk assessment of 
melanoma. 
The study was performed in the frame of a 
SLN protocol conducted by the Groupe Mél-
anome Lémanique. The study protocol was 
approved by the ethical commission and pa-
tients gave their written, informed consent to 
participate. Two hundred and ten successive 
patients entered the study. Patients' character-
istics are shown in Table 1. None of the pa-
tients presented clinical or radiological evi-
dence of metastatic lymph node disease at the 
moment of SLN excision. Breslow thickness 
was comprised between 0.45 and 10.0 mm, 
four patients could not be classified by this 
parameter. Histology typing was: superficial 
spreading in 89 patients among which 15 ul-
cerative, nodular in 69 patients including 23 
ulcerative, acral-lentiginous in23 patients in-
cluding six ulcerative. Six patients presented 
other different histologies and 23 lesions 
were not classified. Clark indices ranged 
from Il to V, six patients being not classified. 
The SLN triple technique, including pre-
operative lymphoscintigraphy, blue color-
ation and per-operative detection with a 
handheld gamma probe, was applied to al! 
patients. All lymphatic nodes identified by 
the triple technique were considered SLN 
and excised. 
Lymphoscintigraphy was realised the 
day before surgery using intradermic injec-
tion of 99mTc-microcolloid (Lymphoscint 
Solco®, n = 54) or 99mTc-nanocolloid (Na-
nocoll®, n = 150) and Nanocis®, n = 6). An 
activity of 10 MBq per site was injected at 
two to six points, depending on lesion size. 
Static imaging of 5 minutes using a matrix 
of256 x 256 and further static imaging of 2 
minutes (matrix 256 x 256) combined with 
an external transmission source was real-
ised. The location of the SLN(s) was/were 
marked in ink on the skin. 
The SLN(s) was/were localised peroper-
atively by radioactivity detection at the la-
belled site(s) using a portable probe ,,Neo-
probe 1000" (Neoprobe Corp., Dublin, 
Ohio, USA) equipped with a detector of 11 
mm diameter or the ,,pol.hi.tech. Scinti-
Probe MR-100" equipped with two detec-
tors of 11 and 18 mm diameter. 
One or several slow (2 to 3 minutes) in-
tradermic injections of patent blue (Pat-
ent V®) or Evans blue (Evans®) were per-
Patient' s characteristics 
patients 
210 
men 107 
women 103 
mean 53.7 
range 15-79 
melanoma upper extremity 39 
localizotion lower extremity 74 
tronc 81 
heod ond neck 16 
Breslow sl.49 72 
thitkness (mm) 1.5-2.38 66 
22.39 68 
unknown 4 
range 
melanoma superficiol spreading 89 
histology 
nodular 69 
acra-lentîginous 23 
others 6 
undassable 16 
unknown 7 
ulceration yes 
no 
245 
formed around the melanoma site or the sur-
gical scar 10 to 15 minutes before surgery. 
The SLN surgery was performed at the site 
defined the day before using lymphoscinti-
graphy and the precise localisation deter-
mined with the hand held gamma probe and 
visual detection of the dye. 
Ail excised SLN were immediately sent for 
histopathological examination without fix-
ation. Alternate slices of 2 mm thickness 
throughout the SLN were subjected to his-
tology and immunohistology analysis. 
Slices were paraffin embedded and 3 to 5 
sections per slice subjected to classical his-
tology using haematoxyline-eosin (HE) 
staining. Immunohistochemistry (IHC) 
analysis was performed for prote in S-1 OO, 
MART-1/Melan-A, Tyrosinase and HMB 
45, except for nine patients for whom histol-
ogy alone was performed. MART-
1/Melan-A, Tyrosinase and HMB 45 are 
proteins specifically expressed by mel-
anocytes and most melanoma while protein 
S-100 is expressed by different neuroendo-
crine tissues and tumours. 
Disease free survival was defined as in-
terval from surgery to first observation of 
relapse. All patients presenting tumour-
negative SLN by HE and IHC criteria were 
followed every 3 to 12 months by clinical 
examination and whole body CT without 
further treatment. Elective node dissection 
was proposed to patients presenting tumour-
positive SLN by HE and/or IHC criteria, in-
dependently from the Breslow index. 
Different clinical and pathological factors 
including age, sex, location and histologi-
cal classification of melanoma, Breslow 
index, ulceration, number and tumour 
positivity/negativity of SLN have been 
analysed as predictive elements of disease 
evolution. Analysis of DFS was performed 
using the Kaplan-Meier method. Univari-
ate and multivariate analysis on the basis 
of Cox's proportional hazards regression 
Nuklearmedizin 6/2007 
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localisation 1 site 2 sites homolaterol 
upper extremity 36 3 (8%) 
lower extremily 71 2 (3%) 
!rune 49 9 (11%) 
head & neck 11 4 (27%) 
total 
2 sites bilateral 3 sites 
0 0 
0 1 (1%) 
21 (25%) 2 (2%) 
1 (7%) 0 
total 
39 
74 
81 
16 
lymphatic droining sites a~alysis. Out of 210 patients 29 relapsed 
wlth local and/or distant disease one to 55 
months after SLN surgery (Tab. 3). 
167 18 22 3 210 
. We observe~ ! 9 relapses which occurred 
m 50 SLN positive patients and IO in 160 
SLN negative ~~tients. Fourty patients out 
~f 50 SLN positive patients accepted elec-
t~ve ~ode re~ection. Ten of them were posi-
model were used to associate covariates to 
DFS: Breslow thickness was treated as a 
cont~nuo.us variable for both univariate and 
mult1vanate analysis. P-values <O 05 'd d . . . were 
cons1 ere s1gmficant. Ali analyses were 
. Co~cerning morbidity after SLN resec-
tlon, six cases. of l~mphocele (3%), four 
cases of local mfection (2%), one case of 
allergy (grade I) against blue dye (0.5%), 
one case of pulmonary embolism (0.5%) 
and one case of scar pain (0.5%) were ob-
served. 
tive m the histopathological examination of t~e complementary nodes. We observed 
e1gh~ recurrences in the group of 10 positive 
elective ono~e resections (80%) and only 
3130 (IOYo)_m the group ofnegative elective 
node resections. 
performed using the BMDP statistical 
Software. 
!~ 210 patients, 385 SLN have been ident-
1~1ed b? lymphoscintigraphy. Iwo addi-
ti.on~l sites (0.5%) identified by lymphos-
cmtigrapy as SLN were false positive and 
corr~sponded to lymphatic lakes. Blue co-
lorat10n detected 375/385 SLN (97%) and 
gamma pro?e 377/385 (98%). Combined 
blue coloration and/or the hand held probe 
allowed the peroperative localization of 
381 SLN.C99%, 1.81 SLN per patient) that 
were e~c1se~ and analysed. For the other 
four sites identified by lymphoscinti-
graphy. (1 %), complementary nodal sur-
gery d1d not allow to find a radioactive 
lymph node. 
A total of 68 (18%) tumour positive SLN 
were observed by HE staining and/or IHC. 
Fo~r~-three SLN were positive by HE 
stammg as well as. IHC, 16 were positive by IH~ .alone ~nd .nme were positive by HE 
stammg whlle mnnunohistology had not 
been performed. Furtheimore, 161 control 
lymph nodes were excised and analysed ~·om 61 patients (2.6 control nodes per pa-
tient). Ail control nodes were negative by 
f.IE and IHC. On a per patient basis 50 pa-
tients out of 210 (24%) had positiv~ nodes 
by HE and/or IHC. 
40150 patients presenting metastases of 
the SLN by HE/IHC criteria had comple-
n:ent~ry el~~tive resection of ail nodes in the 
sites identified for SLN by lymphoscinti-
graphy. Ali complementary resections were 
performed within three months ofSLN sur-
g.ery. From three up to 47 nodes were ex-
c1sed at secondary node surgery. One or 
more further positive nodes were found in 
IO of these 40 patients (25%). 
. At ev~luation, 196 of 210 patients were 
ahve. Thnteen patients had died from dis-
~ase, IO of 19 patients with relapse and posi-
tive SLN, thr~e among the 10 patients who 
relapsed desp1te ne~ative SLN. One patient, 
who was SLN negative and without evidence 
of relapse, ~ad <lied from an unrelated cause. 
Accordmg t? Kaplan-Meier analysis t~e overall surv1Val probability in our pa-
tl~nt population was 92% at three years 
(~1g: ~a). SLN status proved to be the most 
s1gmficant predictive factor of relapse· 
Rela~se probability was 12% in SLN 
negative and 54% in SLN positive patients 
(p <0.~~01): Already at one year relapse 
p~obab1hty m SLN positive patients was 
high (25%), co~pared with only 3% in 
SLN neg~tive patients (Fig. 1 b ). The mean 
Breslow mdex of all patients was 2 32 + 
SD 1.53 mm. It was 2.06 + SD 1 40 . fi 
t. . . mm or pa 1e.nts w1th negative SLN, 3. I 5 + SD 1 69 ~mm SLN positive (HE and/or IHC) ~a­
tients and 3.4 + SD 1.86 mm in patients 
whose tumour recurred. 
. DFS probabi.lity according to Breslow i~de~ .as a contmous variable was highly 
s1gmf1can~ Cp <0:0001). When evaluated 
for three s1mllar s1zed subgroups that pres-
ented Breslow indices of ::;;1.49 (n = n), 
1.5 to 2.38 (n = 66) and ~2.39 (n = 68) th 
overall probability of relapse was 5 25 de 37o/c . , an 
Single SLN_s were detected in I02 patients, 
two SLNs ~n 72 patients and more thand thre~ SLNs m 36 patients. A large number of 
multiples draining sites were observed in 
trun.k .and head & neck melanomas (Tab. 2). 
Drammg ~o three sites, ail homolateral was 
observed m threepatients. 97% of the upper 
and l~wer .extrem1ties drained to the axillary 
and mgumal nodes, respectively while 
t~nc melanomas drained preferentially to 
ax11lary nodes (83%) and head and neck 
melanomas to cervical nodes (44%). 
Mean follow-up after SLN resection was ~ 1.3 months (range: 6-66 months). Four pa-
tients were Iost to follow up 4, 9, 29 and 32 
months respectively after SLN s 
. h . . urgery 
wlt out. ev1dence of relapse and were enter-
o, respectively. Relapse probability at 
one year after surgery in these subgroups 
was 0, 5 an~ 18%, respectively (Fig. le). 
DFS accordmg to sex was close to signifi-
cant (p = 0.06), relapse probability being 
~ 8 and ~8% for women and men respect-
1vely (Fig. Id). ' 
ed cons1dered in live as such in the survival 
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. ~i~tology showed a small trend towards 
s1gn1ficance (p = 0.21), relapse probability 
Major disease and survival parameters of 29 relapsed patients 
sex melanoma SLN elective relapse (month*) fast contrai died lrom disease 
locali. Breslow ulcer histology number HE/IHC resect. local 
F LE 1.47 no superficial s. 1 p p 13 
F LE 2,27 no ac ra-lent 1 p NO 49 
M !rune 5.1 no nodular 2 p NO 
F trune 3.8 no superficial s. 1 p ND 
M !rune 3.2 yes nodular 2 p ND 6 
F LE 2.5 no unknow 1 p p 6 
M UE 2.32 yes superficial s. l p p 
F LE 4 yes nodular 1 p p 13 
9 F H&N 2.7 no other 4 p p 5 
M LE 2.5 yes ocra-lent 2 p p 
M !rune 4 no nodulor 1 p p 
F LE 6.5 yes nodulor 2 p p 12 
M LE 2.4 no nodular 1 p ND 27 
M LE 2.9 no nodular 3 p ND 5 
15 M UE 5.5 na nodular 2 p NO 
16 M LE 9 no ocra-lent 1 p ND 2 
17 M LE 4.4 no nodular 1 p N 4 
18 M trune 3 no superficial s. 2 p N 8 
19 M trunc 2.2 yes superfîcial s. 3 p N 16 
20 M !rune 4 no nodular 2 N ND 8 
21 M UE 2.3 no nodular 1 N ND 10 
22 M H&N 1.8 no superficial s. 1 N ND 34 
23 F LE 2.3 yes superficial s. 1 N ND 18 
24 M H&N 1.2 no unclassable 3 N ND 26 
25 M H&N 2.2 no superlicial s. 2 N ND 
26 M LE 2.3 no nodular 2 N ND 23 
27 M !rune 1.95 no superlicial s. 3 N ND 8 
28 F LE 8 no nodular 1 N ND 36 
29 M UE 2.8 no nodular 1 N ND 26 
P: positive; N: negottve; ND: no! done; UE: upperextremily. lE: lower extremily; H&N: head and neck; 'months after excision of SlN 
being highest for nodular histology. Sur-
vival prediction showed no clear difference 
in trend among the other histological sub-
groups. Primary melanoma localization 
showed a similar trend of difference (p = 
0.21) with the highest probability for re-
lapse for melanoma of the head and neck, 
followed by lower and upper extremities 
melanoma. The other parameters evaluated, 
notably ulceration, age and number of SLN, 
were far from reaching statistical signifi-
cance concerning probability of relapse. 
In the multivariated analysis, the Cox 
analysis indicated that the most important 
risk factor was SLN positivity (p = 0.0001) 
followed by the Breslow index (p = 0.0004) 
and patient's sex (p = 0.055). 
When analysing the relapse probability 
for the combination of Breslow index and 
SLN positivity again in three similar sized 
subgroups defined as 
SLN negative and Breslow index <1.5, 
SLN negative and Breslow index be-
tween 1.5 to 3.5, 
distant in life (month*) (month*) 
20 
34 
4 
1 
6 
7 
17 
13 
11 
1 
27 
33 
2 
25 
15 
16 
19 
42 
26 
34 
55 
27 
34 
63 
59 
51 
18 
24 
8 
34 
22 
15 
3 
18 
41 
46 
33 
19 
43 
21 
20 
47 
21 
42 
39 
34 
34 
31 
12 
55 
32 
SLN positive and/or Breslow >3.5, re-
lapse probabilities were 3, 16 and 48%, 
respectively (Fig. le). 
Finally, SLN positivity in combination with 
a Breslow index of;:2.39 was observed in28 
patients, and 15 of these patients relapsed. 
The Kaplan-Meyer analysis gave a very 
high relapse probability of 72% for these 
patients, the probability in the first year 
being 42% with a 95% confidence interval 
of between 25 and 63%. 
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) 
) 
p 0.8-
r 
0 
b 0.6-
a 
b 
0.4-
y 
0.2 -
0.0 
() 
1 
j 1 1 2 3 
Years 
Patients at risk (Cumulati1·e 1mmber of events) 
1 1 
4 !j 
• 210 (3) 167 (9) 118 (12) 65 (13) 32 (13) 8 (14) 
a) 
p 0.8-
r 
() 
b 0.6-
a 
b 
0.4 -
y 
0.2-
o.o 
.Mantel-Cox Logrank test - 37.26 (df ~ 1) p < 0.0001 
• Negativ 
o Positiv 
1 1 1 1 1 0 1 2 3 4 5 
• 
0 
b) 
Years 
Patients at risk (Cumulative number of events) 
160 (3) 125 (5) 89 (9) <JG (10) 23 (10) 5 (10) 
50 (12) 30 (16) 19 (18) 11 (18) G (19) 2 (ID) 
Overall survival (a) and disease lree survival (b-e); vertical bars: 95% confidence interval 
overall survival probability: 92% al three years 
histology between negative and positive SLN patients; overall relapse probability (3 years): 10% and 45% 
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This study aimed at evaluating SLN scinti-
graphy in early stage melanoma. A second 
aim was the evaluation of the prevalence of 
tumour recurrence in SLN positive patients. 
Performed as multicenter study, scinti-
graphy was analysed as part of the triple 
SLN detection method. Immunohisto-
chemical analysis was performed for four 
parameters. 
RT-PCR evaluation was performed in a 
subgroup of these patients. These results 
have been presented previously (11 ). Over-
all, we did not observe any particular differ-
ence of relapse probability between RT-
PCR positive and negative patients. None of 
the RT-PCR positive patients with negative 
HE/IHC evaluation presented a relapse in 
this evaluation. ln fact, the debate on the rel-
evance of PCR as a predictive factor for re-
lapse in melanoma patients remains open (2, 
3). RT-PCR positive and HE/IHC negative 
patients might represent a subgroup of pa-
tients with very minor disease. The survival 
probability of these patients appears to be 
better in the first years than that of HE/IHC 
SLN positive patients, but they might be 
prone'to relapse at a later stage. 
The lymphatic imaging of SLN in mel-
anoma patients allowed visualising all 381 
SLN in this cohort of 210 patients in the 
sense that no further SLN were detected by 
the blue coloration method and the gamma 
probe. However, while these latter methods 
revealed essential and complementary in-
formation for surgery, a few SLN were 
missed (1 %) even when using the com-
bination of both of them. In the absence of 
the peroperative SLN identification selec-
. ' tlve surgery of the relevant lymph node 
basin had to be performed and the histologi-
cal analysis of the multiple lymph nodes was 
therefore suboptimal. 
In view of the high detection rate of 
>97% with each of the preoperative meth-
ods, one or the other method might be 
chosen by the surgeon without major change 
in the selective SLN resection rate. However, 
the combination of blue coloration and 
gamma probe technique allowed to resect 
and analyse the highest percentage of SLN. 
Scintigraphy had a false positive detection 
rate of 2/385 (0.5%), both false positives 
being due to lymphatic lakes. This already 
low rate could possibly be further reduced by 
using late imaging, however the gain might 
be judged insufficient in this pathology. 
In view of the favourable detection rate 
of SLN by scintigraphy, it is confirmed here 
that this method is essential in SLN surgery 
of melanoma. It notably allowed in many pa-
tients to become aware of multiple draining 
sites of melanoma, especially when situated 
on the trunk and close to the median line. 
However, also infrequent localisation of 
SLN such as popliteal or humerai sites 
could be identified and allowed the surgeon 
to programthe intervention adequately. 
When considering the histopathological 
examination, we found a clear difference 
between the classical HE coloration and im-
munohistochemistry in favour of the latter 
one. White ail HE positive SLN that were 
also examined by immunohistochemistry 
were confirmed, the latter method detected 
a significantly higher number of metastases. 
We used the overall detection rate of these 
two methods to correlate it with the clinical 
outcome. The combination of both tech-
niques was necessary, since immunohisto-
chemistry could not be performed in a few 
occasions. 
In this series, 24% of patients presented 
tumour positive SLN by HE/IHC criteria. 
When analysing SLN positivity according 
to histological criteria, nodular melanoma 
showed the highest incidence of SLN posi-
tivity (35%), followed by acral-lentiginal 
histology (26%) and superficial spreading 
melanoma (16%). These results differ par-
tially from those described by Vuylsteke et 
al. (14) who found similarly that nodular 
melanoma had the highest probability for 
SLN positivity, followed, however, by super-
ficial spreading in his series. Acral lentigi-
nal melanoma, which presented only 1 % in 
the patient population of Vuylsteke com-
pared with 11 % in our group, had no par-
ticular tendency for SLN positivity. 
In this study, primary melanoma located 
on the legs as compared to other locali-
sations showed a higher incidence of SLN 
positivity. A correlation of SLN positivity 
with primary tumours on the appendices has 
been described previously by Rousseau et 
al. (12). 
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We observed 29 tumour relapses one to 5 5 
months post surgery of primary melanoma. 
The univariate and multivariate analysis 
showed that the highest risk factors for re-
lapse were those of SLN positivity and a high 
Breslow index. SLN positivity and a Breslow 
index above 2.38 turned out as strong predic-
tive factors of early relapse in agreement with 
the observations of Vuylsteke et al. (14), 
Mozzillo et al. (8), Rousseau et al. (12) and 
Morton et al. (6). Ulceration has been de-
scribed as another predictive factor of relapse 
by two of the three mentioned authors (8, 14). 
However, this was not the case in the patient 
population presented here. This study in-
cluded 53 patients with ulcerated melanoma. 
Their risk of relapse appeared only margin-
ally higher (p = 0.58) than that of patients 
without ulceration. 
Relapse probability according to pa-
tient's sex was close to significant (p = 0 .06) 
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with more than 50% increased relapse prob-
ability for men compared with women. Con-
cerning tumour histology, some tendency 
was observed (p = 0.21), nodularmelanoma 
showing a highest probability of tumour re-
currence. However, the number of patients 
per subgroup was small, the observation 
period short and thus do not permit a con-
clusive statement. Similarly, localization of 
primary melanoma showed only some ten-
dency of discrimination for relapse. How-
ever, age and number of SLN, were far from 
showing any tendency as predictive factors 
for recurrence. 
Our statistical analysis has shown the 
very similar contribution of SLN positivity 
and a high Breslow index for defining pa-
tients with high risk of early relapse. This 
observation prompted the evaluation of dif-
ferent combination of these two parameters. 
Patients presenting simultaneously the two 
risk factors have a very high relapse prob-
ability. The association between Breslow 
index and SLN status furthermore allowed 
to grouping the patients according to their 
relapse probabilities. These groups in turn 
could profit from therapies of differential 
aggressiveness, depending on the individual 
patients relapse probability. 
This study confirmed the particular rel-
evance of lymph node scintigraphy in the 
context of carefully performed blue colour 
and gamma probe detection technique in the 
SLN approach of early stage melanoma. 
Furthermore, we showed that the SLN status 
and the Breslow index are independent, 
strong predictive factors for early relapse in 
patients with early stage melanoma. The 
combination of these two parameters allow-
ed the subdivision of patients in groups with 
very high, intermediate and low risk of re-
lapse and might lead consequently to the 
adaptation of therapy protocols according to 
the individual risk. 
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